神州百济BGB3111 试验报告解读-201906 阿姆斯特丹发布

摘要:  UPDATED SAFETY AND EFFICACY DATA FROM A COHORT OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA IN A PHASE 1/2 TRIAL TREATED WITH THE BRUTON TYROSINE KINASE INHIBITOR ZANUBRUTINIB (BGB-3111)

下载报告,请点击以下红色字体链接:

UPDATED SAFETY AND EFFICACY DATA FROM A COHORT OF PATIENTS
WITH WALDENSTRÖM MACROGLOBULINEMIA IN A PHASE 1/2 TRIAL
TREATED WITH THE BRUTON TYROSINE KINASE INHIBITOR ZANUBRUTINIB
(BGB-3111)

如果文章对你有帮助,欢迎点击上方按钮打赏作者

觉得文章有用就打赏一下文章作者

微信扫一扫打赏

返回顶部